<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106297</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG3970-CL-101</org_study_id>
    <secondary_id>2019-001803-19</secondary_id>
    <nct_id>NCT04106297</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970</brief_title>
  <official_title>A First-in-human, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GLPG3970 Single and Multiple Ascending Doses in Adult Healthy Male Subjects, and in Psoriasis Subjects When Administered Daily for 6 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of GLPG3970 in
      healthy volunteers after single oral administrations of GLPG3970 (SAD), compared to placebo
      (part 1) and after multiple (for 14 days) oral administrations of GLPG3970 (MAD), compared to
      placebo (part 2). The effect of food (FE) (high-fat, high calorie) on the pharmacokinetics of
      GLPG3970 and the relative bioavailability (rBA) of an oral solution versus a solid
      formulation will be assessed (part 3 and 3bis). Part 4 of the study is to evaluate the safety
      and tolerability of GLPG3970 in psoriasis subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1 (SAD), Part 2 (MAD) and Part 4 (MAD in psoriasis subjects) are randomized, double-blind, placebo-controlled; Part 3 (FE-rBA) and Part 3bis (FE) are randomized, open-label.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs), treatment-emergent serious adverse events, and TEAEs leading to treatment discontinuations</measure>
    <time_frame>From screening through study completion, an average of 15 months</time_frame>
    <description>To evaluate the safety and tolerability of GLPG3970 compared to placebo in adult healthy male subjects as single and multiple ascending oral doses, and in psoriasis subjects when administered daily for 6 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLPG3970 (Part 1)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the pharmacokinetics (PK) of oral SAD of GLPG3970 in adult healthy male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLPG3970 (Part 2)</measure>
    <time_frame>Between Day 1 pre-dose and Day 17</time_frame>
    <description>To evaluate the PK of oral MAD of GLPG3970 in adult healthy male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLPG3970 (Part 3 and 3bis, FE)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the food effect on the PK of a single oral dose of GLPG3970 in adult, healthy, subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLPG3970 (Part 3, rBA)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the PK of a single oral dose of GLPG3970 administered as an oral solution versus and oral capsule in adult, healthy, subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) of GLPG3970 (Part 1)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the PK of oral SAD of GLPG3970 in adult healthy male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) of GLPG3970 (Part 2)</measure>
    <time_frame>Between Day 1 pre-dose and Day 17</time_frame>
    <description>To evaluate the PK of oral MAD of GLPG3970 in adult healthy male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) of GLPG3970 (Part 3 and 3bis, FE)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the food effect on the PK of a single oral dose of GLPG3970 under fed conditions (high-fat high calorie) versus fasted conditions in adult, healthy, subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) of GLPG3970 (Part 3, rBA)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the rBA of an oral solution of GLPG3970 versus an oral capsule of GLPG3970 on the PK of a single oral dose of GLPG3970 in adult, healthy, subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) of GLPG3970 (Part 1)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the PK of oral SAD of GLPG3970, in adult, healthy, subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) of GLPG3970 (Part 2)</measure>
    <time_frame>Between Day 1 pre-dose and Day 17</time_frame>
    <description>To evaluate the PK of oral MAD of GLPG3970, in adult, healthy, subjects</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>GLPG3970 SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of GLPG3970 at up to 6 dose levels in ascending order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3970 MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of GLPG3970 at up to 3 dose levels in ascending order, daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3970 FE-rBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG3970 in fed and fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3970 FE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG3970 in fed and fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3970 in psoriasis subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in psoriasis subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3970 oral solution</intervention_name>
    <description>GLPG3970 for oral administration</description>
    <arm_group_label>GLPG3970 FE</arm_group_label>
    <arm_group_label>GLPG3970 FE-rBA</arm_group_label>
    <arm_group_label>GLPG3970 MAD</arm_group_label>
    <arm_group_label>GLPG3970 SAD</arm_group_label>
    <arm_group_label>GLPG3970 in psoriasis subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral solution</intervention_name>
    <description>Placebo for oral administration</description>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_label>Placebo SAD</arm_group_label>
    <arm_group_label>Placebo in psoriasis subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3970 capsule</intervention_name>
    <description>GLPG3970 for oral administration</description>
    <arm_group_label>GLPG3970 FE-rBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male between 18-55 years of age (extremes included), on the date of signing the
             informed consent form (ICF).

          -  A body mass index (BMI) between 18-30 kg/m2, inclusive.

          -  Judged to be in good health by the investigator based upon the results of a medical
             history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and
             fasting clinical laboratory safety tests available at screening and prior to
             randomization. Hemoglobin must not be below the lower limit of normal range.
             Bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) must
             be no greater than 1.5x upper limit of normal range (ULN). Other clinical laboratory
             safety test results must be within the reference ranges, or test results that are
             outside the reference ranges need to be considered not clinically significant in the
             opinion of the investigator.

        This list only contains the key inclusion criteria for the healthy volunteers part of the
        study.

        Exclusion Criteria:

          -  Known hypersensitivity to the Investigational Medicinal Product (IMP) ingredients or
             history of a significant allergic reaction to IMP ingredients as determined by the
             investigator.

          -  Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus
             or history of hepatitis from any cause with the exception of hepatitis A that was
             resolved at least 3 months prior to first dosing of the IMP.

          -  History of or a current immunosuppressive condition (e.g. human immunodeficiency virus
             [HIV] infection).

        This list only contains the key exclusion criteria for the healthy volunteers part of the
        study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Petkova, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galapagos Medical Information</last_name>
    <phone>+32 15 34 29 00</phone>
    <email>medicalinfo@glpg.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SGS Belgium NV - Clinical Pharmacology Unit Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

